Risk Factors in Cases of ESBL-Positive E. coli Isolated from Urine Cultures in Community-Acquired Urinary Tract Infections in Children

Year 2025, Volume: 4 Issue: 3, 93 - 100, 30.09.2025

Selma Oktay Ergin , Feyza Mediha Yıldız

Abstract

Introductıon: Extended-spectrum β-lactamase (ESBL)-producing Escherichia (E.) coli has become an increasing concern in pediatric community-acquired urinary tract infections (UTIs). The primary aim of this study is to investigate and identify the clinical, demographic, and medical history-related risk factors associated with ESBL-producing E. coli strains isolated from urine cultures of pediatric patients diagnosed with community-acquired UTIs.

Methods: : We retrospectively reviewed 100 pediatric patients with ESBL-positive E. coli UTIs hospitalized between 2008–2012, all of whom received meropenem therapy. Risk factors, clinical manifestations, urine collection methods, comorbidities, and prior antibiotic exposure were collected.

Results:ESBL-positive E. coli UTIs were more frequent in boys during the neonatal period but became predominant in girls thereafter, with the highest prevalence under two years of age. Clinical manifestations vary with age, ranging from nonspecific symptoms such as fever and vomiting in infants to typical complaints like abdominal pain and dysuria in older children. E. coli was identified as the leading pathogen, while high resistance rates to commonly used antibiotics (ampicillin, amoxicillin/clavulanate, TMP-SMX) were observed. Carbapenems remained the most effective agents, though their use should be reserved due to cost and hospitalization requirements. Underlying urinary tract abnormalities, vesicoureteral reflux, recurrent infections, and recent antibiotic exposure were major risk factors for ESBL (+) UTIs.

Conclusion: Our results highlight the clinical significance of ESBL-producing E. coli in pediatric UTIs. Early recognition of risk factors, careful diagnostic evaluation, and rational antibiotic selection are crucial for optimal management.

Keywords

ESBL-Positive E. coli , Urine Cultures , Urinary Tract Infections

References

• 1. Oliveira, E.A. and R.H. Mak, Urinary tract infection in pediatrics: an overview. Jornal de pediatria, 2020. 96: p. 65-79.
• 2. Tullus, K. and N. Shaikh, Urinary tract infections in children. The Lancet, 2020. 395(10237): p. 1659-1668.
• 3. Hanna-Wakim, R.H., et al., Epidemiology and characteristics of urinary tract infections in children and adolescents. Frontiers in cellular and infection microbiology, 2015. 5: p. 45.
• 4. Velioglu, A., et al., Incidence and risk factors for urinary tract infections in the first year after renal transplantation. PLoS One, 2021. 16(5): p. e0251036.
• 5. Murugapoopathy, V., C. McCusker, and I.R. Gupta, The pathogenesis and management of renal scarring in children with vesicoureteric reflux and pyelonephritis. Pediatric Nephrology, 2020. 35(3): p. 349-357.
• 6. Breinbjerg, A., et al., Risk factors for kidney scarring and vesicoureteral reflux in 421 children after their first acute pyelonephritis, and appraisal of international guidelines. Pediatric Nephrology, 2021. 36(9): p. 2777-2787.
• 7. Ena, J., et al., Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology, 2006. 68(6): p. 1169-1174.
• 8. Pitout, J.D., Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs, 2010. 70(3): p. 313-333.
• 9. Padmini, N., et al., Extended spectrum β‐lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern. Journal of basic microbiology, 2017. 57(6): p. 460-470.
• 10. Karaiskos, I. and H. Giamarellou, Carbapenem-sparing strategies for ESBL producers: when and how. Antibiotics, 2020. 9(2): p. 61.
• 11. Tamma, P.D., et al., Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 2022. 75(2): p. 187-212.
• 12. Salihu, M., A. Yarima, and H. Atta, Methods for the phenotypic detection of extended spectrum beta lactamase (ESBL)-producing bacteria. Nigerian Journal of Biotechnology, 2020. 37(2): p. 113-125.
• 13. Ekpunobi, N., et al., Antimicrobial Resistance in Pediatric UTIs: Molecular Profiles, Clinical Burden, and Public Health Implications of ESBL-Producing Uropathogens. 2025.
• 14. Isiaka, H.S., Diversity and Antibiotic Susceptibility of Bacteria from Urine Samples of Catheterized Patients at the University of Ilorin Teaching Hospital. 2022, Kwara State University (Nigeria).
• 15. Mancuso, G., et al., Urinary tract infections: the current scenario and future prospects. Pathogens,2023. 12(4): p. 623.
• 16. Alzomor, O.A., Community Acquired Urinary Tract Infections in Children: Prevalence and Predictive Factors for ESBL Status of Uropathogen in a Tertiary Care Center in Saudi Arabia. 2024, Alfaisal University (Saudi Arabia).
• 17. McDonald, K.L., et al., Measures used to assess the burden of ESBL-producing Escherichia coli infections in humans: a scoping review. JAC-antimicrobial resistance, 2021. 3(1): p. dlaa104.
• 18. Peirano, G. and J.D. Pitout, Extended-spectrum β-lactamase-producing Enterobacteriaceae: update on molecular epidemiology and treatment options. Drugs, 2019. 79(14): p. 1529-1541.
• 19. ARMAN, D.Ç., Çocukluk Çaği Üriner Sistem İnfeksiyonlarina Yol Açan Etkenlerin Dağılmı Ve Antibiyotik Duyarlılıklarının Araştrılması. Uzmanlık Tezi, Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi, İstanbul; 2008: 40-58.
• 20. GÖK, F. and D.Ö. Hacihamdioğlu, İdrar Yolu Enfeksiyonlu Çocukta Yaklaşım ve Tedavi. Turkiye Klinikleri Urology-Special Topics, 2010. 3(2): p. 27-38.
• 21. Yalçinkaya, F.F., Çocukluk Çağında İdrar Yolu Enfeksiyonları ve Vezikoüreteral Reflü. Turkiye Klinikleri Pediatric Sciences-Special Topics, 2008. 4(1): p. 42-48.
• 22. Yüksel, S., et al., Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections. International journal of antimicrobial agents, 2006. 28(5): p. 413-416.
• 23. Roberts, K.B. and O.B. Akintemi, The epidemiology and clinical presentation of urinary tract infections in children younger than 2 years of age. 1999, SLACK Incorporated Thorofare, NJ. p. 644-649.
• 24. Mir, S., et al., Çocukluk çağı idrar yolu enfeksiyonlarında ilk tedavi seçeneği ne olmalıdır. Türk Nefrol Diyal Transplant Derg, 1997. 2(3-4): p. 149-53.
• 25. Alpay, H., et al., Clinical and metabolic features of urolithiasis and microlithiasis in children. Pediatric nephrology, 2009. 24(11): p. 2203-2209.
• 26. Elzouki, A., N. Mir, and O. Jeswal, Symptomatic urinary tract infection in pediatric patients--a developmental aspect. The International Journal of Pediatric Nephrology, 1985. 6(4): p. 267-270.
• 27. Başhan, İ., Pediatrik Hasta Üriner Sistem Enfeksiyonlarının Birinci Basamaktaki Yönetimi. Turkiye Klinikleri Family Medicine-Special Topics, 2012. 3(5): p. 36-41.
• 28. Anis-ur-Rehman, J.M., T.S. Siddiqui, and M. Idris, Frequency and clinical presentation of UTI among children of Hazara Division, Pakistan. J Ayub Med Coll Abbottabad, 2008. 20(1): p. 63.
• 29. Bouallègue, O., et al., Bacteriologic features of urinary tract infections in children in the Sousse area, Tunisia. La Tunisie Medicale, 2004. 82(8): p. 742-746.
• 30. Haller, M., M. Brandis, and R. Berner, Antibiotic resistance of urinary tract pathogens and rationale for empirical intravenous therapy. Pediatric nephrology, 2004. 19(9): p. 982-986.
• 31. Afsharpaiman, S., et al., Bacterial pathogens and resistance patterns in children with community-acquired urinary tract infection: a cross sectional study. Journal of Comprehensive Pediatrics, 2012. 3(1): p. 16-20.
• 32. Yilmaz, R., et al., Çocuklarda idrar yolları enfeksiyonu etkenleri ve antibiyotik duyarlılıkları. Çağdaş Tıp Dergisi, 2012. 2(1): p. 17-21.
• 33. Hoberman, A., et al., Imaging studies after a first febrile urinary tract infection in young children. New England Journal of Medicine, 2003. 348(3): p. 195-202.
• 34. Karımov, S., Akut Pyelonefrit Geçirmiş 0-5 Yaş Arası Çocuklarda Renal Skar Tanısında Prokalsitoninin Prediktiv Değeri. 2016, Ankara Universitesi (Turkey).
• 35. Boyraz, M.S., Genişlemiş Spektrumlu Beta-Laktamaz (ESBL) Üreten Mikroorganizmalarla Gelişen Üriner Enfeksiyonlu Çocukların Klinik ve Laboratuvar Bulguları. 2014.
• 36. Rodríguez-Bano, J., et al., Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. Journal of clinical microbiology, 2004. 42(3): p. 1089-1094.